The monkeypox virus is already present in more than 80 countries and its expansion could mean another crisis in health systems, which is why officials are considering vaccination to combat the disease in a timely manner.
Despite the fact that weeks ago the World Health Organization recognized that mass vaccination was not necessary, but for people who are in high-risk locations, such as those working in hospitals or caring for patients, its The subsidiary, the Pan American Organization’s Department of Health (PAHO), is already working to help manage the case of the U.S.’s acquisition of a traditional smallpox vaccine that, according to studies, works for monkeys, but with the same priority criteria.
The fact that smallpox vaccines are rarely produced is another challenge in being able to distribute them equitably among all affected countries to the extent that new infections are diagnosed every day.
In Europe, for example, at the time of the outbreak last May, countries such as the Netherlands had stockpiles of vaccines and weeks later began giving them to people with close contacts.
In addition, as of this 10 August, the WHO alone had at least 2.4 million doses deposited in Geneva, Switzerland, while another 31 million have been deposited by five countries that are already making vaccination and reinforcement plans: France, Germany, New Zealand, United Kingdom and United States of America.
In other cases, such as Spain, they are managing the purchase of several batches of Imvanex dosages developed by the Danish laboratory Bavarian Nordic; However, in many regions they are already administering vaccines and especially in Madrid they are proposing to split a dosing plan to five people due to shortages. As of last Tuesday, August 2, the European country had received 5,300 vaccines against monkeypox and another 7,000 are expected.
Officially, smallpox was eradicated in the 1980s and the outbreak now known as monkeypox refers to another strain of the disease, so the effectiveness of traditional smallpox vaccines is limited only to Denmark, Japan and the United States. Manufactured by.
In this sense, in Latin America, where there are more than 10,000 reported cases, PAHO director Carissa Etienne has said that the major problem is the lack of vaccines and that only a third generation is available.
Faced with this situation, some authorities are considering taking steps to vaccinate their population. In Ecuador, the health ministry said it was exploring options to buy supplements in Switzerland and Canada, despite low production of the drugs.
In Peru, as of mid-July last, health officials were still evaluating the acquisition of antidotes, noting that by that date it had already reported more than 200 infections.
One factor against this is the high cost of vaccination, the government assured. This is also the case in Chile, where the Ministries of Health and Foreign Affairs manage procurement with PAHO to finalize dose arrivals and carry out the vaccination plan in conjunction with the Advisory Committee on Vaccines and Immunization.
In general, almost all countries in the Latin American region are evaluating the acquisition of the traditional vaccine Jynneos because it is registered in the US, or Imvanex as it is known in Europe, and which is a third generation preparation, the last one made. is against smallpox.
In addition, there is a fourth generation vaccine candidate being developed by the Russian Federation; However, it is still unknown when it will be available.
vaccine in america
The last US purchase of vaccines was in 2012 during the government of Barack Obama for 20 million doses.
Currently, in the North American country, with part of their stockpiles, they complete vaccination days in North Carolina, New York, Miami (Florida) and other places in the country, where they use one-fifth of each vaccine by injection. also plan to do. ,
smallpox in venezuela
In Venezuela, as in many other countries, the traditional vaccine, Imvanex or also known as Genios or Imvaimmune, was stopped in 1980, which has been shown to be effective and may provide substantial protection.
However, according to recent statements by Enrique López, president of the National Academy of Medicine, that mass vaccination was abandoned in the 1980s, following the eradication of the disease, “the population lost its immunity, as well as other related viruses. Against, in the middle that is found in monkeypox.”
He said the new specifications for the fight against the smallpox virus have not been properly expanded into use around the world because they were created for endemic areas, and stressed that a case has been quickly identified near Venezuela. There are tests to do.